Stock News

The Schall Law Firm Reminds Investors of Class Action Lawsuit Against PDD Holdings Inc. Los Angeles, CA / ACCESSWIRE / September 14, 2024 The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PDD Holdings Inc. f/k/a Pinduoduo Inc. (“PDD” or “the Company”) (NASDAQ:PDD) for violations of…

Investors Alert: Securities Class Action Lawsuit Filed Against Extreme Networks, Inc. Introduction The law firm of Kessler Topaz Meltzer & Check, LLP recently announced the filing of a securities class action lawsuit in the United States District Court for the Northern District of California against Extreme Networks, Inc. (“Extreme”) on behalf of investors who purchased…

Empowering Cancer Patients with Pfizer’s Breakthrough Study A Beacon of Hope In a groundbreaking development, Pfizer Inc. has announced a significant milestone in the battle against cancer cachexia. The Phase 2 study of ponsegromab, a monoclonal antibody targeting growth differentiation factor-15 (GDF-15), has shown promising results in improving body weight in individuals with cancer cachexia…

The Impact of the WEBTOON Class Action Lawsuit Introduction In a recent announcement by Robbins Geller Rudman & Dowd LLP, purchasers or acquirers of WEBTOON Entertainment Inc. (NASDAQ: WBTN) common stock have been given a deadline to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit, titled Brookman v. WEBTOON Entertainment Inc.,…

Class Action Lawsuit Filed Against Spire Global, Inc. New York City, NY / ACCESSWIRE / September 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Spire Global, Inc. (“Spire” or “the Company”) (NYSE:SPIR) and certain of its officers. Class Definition…

Charmingly Eccentric: BioInvent International Presents Preliminary Data on BT-001 LUND, SWEDEN / ACCESSWIRE / September 14, 2024 BioInvent International (STO:BINV) Preliminary Data At the recent ESMO 2024 conference in Lund, Sweden, BioInvent International presented preliminary data on their groundbreaking treatment, BT-001. This innovative therapy has shown promising results in inducing tumor regression in patients who…

Nuvalent Presents Clinical Data at ESMO 2024 for ROS1 and ALK-Positive NSCLC Lead Programs with Accelerated Development Timelines Description: Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655. Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials. Pivotal data…

Pfizer Inc. Releases Longer-Term Follow-Up Results from PHAROS Clinical Trial What the Latest Results Mean In an exciting development for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC), Pfizer Inc. has announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial. The trial evaluated the efficacy and safety of BRAFTOVI® (encorafenib)…